



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 866 131 A3**

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
15.12.1999 Bulletin 1999/50

(43) Date of publication A2:
23.09.1998 Bulletin 1998/39

(21) Application number: 98302113.0

(22) Date of filing: 20.03.1998

(51) Int Cl.⁶: **C12N 15/62**, C07K 16/00,
C07K 16/28, C12N 15/70,
C12N 1/21, A61K 39/395

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 21.03.1997 JP 6793897

(71) Applicant: **Sankyo Company Limited**
Chuo-ku, Tokyo 103-8426 (JP)

(72) Inventors:
• **Serizawa, Nobufusa,**
c/o Sankyo Company Limited
Shinagawa-ku, Tokyo (JP)

- **Haruyama, Hideyuki,**
c/o Sankyo Company Limited
Shinagawa-ku, Tokyo (JP)
- **Takahashi, Tohru,** c/o Sankyo Company Limited
Shinagawa-ku, Tokyo (JP)
- **Nakahara, Kaori,** c/o Sankyo Company Limited
Shinagawa-ku, Tokyo (JP)
- **Yonehara, Shin**
Kyoto-shi, Kyoto-fu (JP)

(74) Representative: **Gibson, Christian John Robert**
MARKS & CLERK,
57/60 Lincoln's Inn Fields
London WC2A 3LS (GB)

(54) **Humanized anti-human fas antibody**

(57) The invention provides humanised anti-human Fas antibodies capable of inducing apoptosis in cells expressing Fas and which are useful in the treatment of

autoimmune disease and chronic rheumatoid arthritis. In addition, the invention provides DNA encoding the variable regions of the H and L chain of such antibodies and methods for humanising antibodies.

EP 0 866 131 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 98 30 2113

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	WO 92 22653 A (GENENTECH INC) 23 December 1992 (1992-12-23) * page 11, line 19-25 * * page 26, line 23 - page 28, line 5 * * page 48, line 20 - page 49, line 17 * * page 50, line 14 - page 51, line 10 * * example 2 *	1-6,8-17	C12N15/62 C07K16/00 C07K16/28 C12N15/70 C12N1/21 A61K39/395
Y	---	7,18-20, 29-44	
Y	EP 0 709 097 A (SANTEN PHARMA CO LTD ;LLT INST CO LTD (JP)) 1 May 1996 (1996-05-01) * page 4, line 3-14 * * page 3, line 54 - page 5, line 8 * * claims *	7,18-20, 29-44	
X	KETTLEBOROUGH C A ET AL: "HUMANIZATION OF A MOUSE MONOCLONAL ANTIBODY BY CDR-GRAFTING: THE IMPORTANCE OF FRAMEWORK RESIDUES ON LOOP CONFORMATION" PROTEIN ENGINEERING, vol. 4, no. 7, 1 October 1991 (1991-10-01), pages 773-783, XP002030588 ISSN: 0269-2139 * abstract * * figures 4,5 *	1-6,8-17	TECHNICAL FIELDS SEARCHED (Int.Cl.6) C07K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 20 October 1999	Examiner Covone, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03/82 (PtdC01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 98 30 2113

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	FOOTE J ET AL: "ANTIBODY FRAMEWORK RESIDUES AFFECTING THE CONFORMATION OF THE HYPERCARIABLE LOOPS" JOURNAL OF MOLECULAR BIOLOGY, vol. 224, no. 2, 1 January 1992 (1992-01-01), pages 487-499, XP000564649 ISSN: 0022-2836 * page 488, left-hand column, paragraph 2 - page 489, left-hand column, paragraph 1 * * figure 1 *	1-6,8-17	
A	DATABASE EMBL, PIR2: "Accession number: S37768" RESIDUES: 1-453, XP002119669 * the whole document * & HARINDRANATH N ET AL.: "Comparison of complete nucleotide sequence of the human IgM heavy chain constant region of polyreactive and monoreactive antibodies" MOL.IMMUNOL., vol. 30, 1993, pages 111-2, ---	21-28	
A	WO 95 10540 A (IMMUNEX CORP) 20 April 1995 (1995-04-20) * claims 1,19 * * page 2, line 6-17 * ---	1-44	
P,X, L	EP 0 799 891 A (SANKYO CO) 8 October 1997 (1997-10-08) * page 2, line 48 - page 3, line 25 * * page 6, line 39 - page 7, line 26 * * page 9, line 6.13 * * claims 1,9,20,32-35 * --- -/--	1-20, 29-44	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 20 October 1999	Examiner Covone, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons 3 : member of the same patent family, corresponding document	

EPO FORM 1503 (03.82) (P04001)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 98 30 2113

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
T	<p>DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US SERIZAWA, NOBUFUSA: "Trials on the development of drug by an novel anti- Fas monoclonal antibody" retrieved from STN Database accession no. 130:266049 HCA XP002119670 * abstract * & SAISHIN IGAKU (1999), 54(4), 917-924 , -----</p>	1-44	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 20 October 1999	Examiner Covone, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/92 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 30 2113

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-10-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9222653 A	23-12-1992	AU 675916 B	27-02-1997
		AU 2250992 A	12-01-1993
		CA 2103059 A	15-12-1992
		EP 0590058 A	06-04-1994
		EP 0940468 A	08-09-1999
		JP 6508267 T	22-09-1994
		WO 9404679 A	03-03-1994
		US 5821337 A	13-10-1998
EP 0709097 A	01-05-1996	CA 2158822 A	28-03-1996
		JP 8208515 A	13-08-1996
WO 9510540 A	20-04-1995	AU 705114 B	13-05-1999
		AU 7978494 A	04-05-1995
		CA 2174132 A	20-04-1995
		EP 0723556 A	31-07-1996
		JP 9503672 T	15-04-1997
		NZ 275711 A	25-03-1998
		US 5620889 A	15-04-1997
		US 5830469 A	03-11-1998
EP 0799891 A	08-10-1997	AU 1655297 A	09-10-1997
		CA 2201185 A	01-10-1997
		CN 1167115 A	10-12-1997
		CZ 9700963 A	15-10-1997
		HU 9700676 A	28-01-1998
		JP 9322796 A	16-12-1997
		NO 971448 A	02-10-1997
		NZ 314496 A	25-02-1999

EPO FORM P0455

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)